| Tejon Urges Shareholders to Vote “FOR” ONLY the Company's 10 Highly Qualified Director Nominees on the WHITE Proxy Card Ahead of Tomorrow's Annual Meeting |
TEJON RANCH, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE: TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today reminded all Tejon shareholders to vote “FOR” ONLY Tejon's 10 highly qualified director nominees on the Company's WHITE Proxy Card in connection with its Annual Meeting of Shareholders scheduled for May 13, 2025. Additional information, including details on how to vote, can be found at www.VoteForTejon.com . |
globenewswire.com |
2025-05-12 13:15:00 |
Czytaj oryginał (ang.) |
| Kern County leaders sign letter supporting Tejon's Board |
State legislators, County supervisors highlight critical role of Tejon Master Planned Communities for economic development and growth State legislators, County supervisors highlight critical role of Tejon Master Planned Communities for economic development and growth |
globenewswire.com |
2025-05-09 16:47:00 |
Czytaj oryginał (ang.) |
| Glenbrook Welcomes CalSTRS' Support of PFS Trust's Shareholder Proposal and Bulldog's Director Slate |
Urges Shareholders to Vote on Bulldog's GREEN Proxy Card at Tejon Annual Meeting of Shareholders PALO ALTO, Calif. , May 9, 2025 /PRNewswire/ -- Glenbrook Capital Management ("Glenbrook" or "we"), a long-time shareholder of Tejon Ranch Co. (NYSE:TRC) ("Tejon" or the "Company") and owner of approximately 1.1% of outstanding shares of the Tejon, thanks CalSTRS for its vote FOR both Item #4 to allow Tejon shareholders owning a combined 10% of outstanding shares to call a special meeting of shareholders and FOR Bulldog Capital's state of nominees ("Bulldog's Slate") to the Tejon Board of Directors (the "Board") on Bulldog's GREEN Proxy Card. |
prnewswire.com |
2025-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Announces First Quarter 2025 Financial Results |
TEJON RANCH, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the three-months ended March 31, 2025. |
globenewswire.com |
2025-05-08 20:15:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co.'s Refreshed and Highly Qualified Board is Best Positioned to Create Long-Term Value and Realize Tejon's Strategic Goals |
Bulldog's Nominees Lack the Experience Needed to Guide Tejon Independent Third Parties Recognize Deficiencies in Bulldog's Nominees and Campaign Tejon Urges Shareholders to Vote the WHITE Proxy Card "FOR” ALL 10 of the Company's Director Nominees TODAY TEJON RANCH, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today mailed a letter to shareholders in connection with its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) to be held on May 13, 2025. |
globenewswire.com |
2025-05-08 13:15:00 |
Czytaj oryginał (ang.) |
| Glenbrook Capital Management Issues Statement Highlighting ISS and Glass Lewis Support of PFS Trust's Shareholder Proposal to Enable Tejon Ranch Shareholders to Call Special Meetings |
Supports Bulldog Capital Nominees to Tejon Ranch Board of Directors PALO ALTO, Calif. , May 7, 2025 /PRNewswire/ -- Glenbrook Capital Management ("Glenbrook" or "we"), long-time shareholders of Tejon Ranch Co. (NYSE:TRC) ("Tejon" or the "Company") and owners of approximately 1.1% of outstanding shares of the Tejon, today issued the following statement outlining their intention to vote FOR Item #4 to allow Tejon shareholders owning a combined 10% of outstanding shares to call a special meeting of shareholders and FOR Bulldog Capital's state of nominees ("Bulldog's Slate") to the Tejon Board of Directors (the "Board"), at the May 13 Tejon Annual Meeting of Shareholders (the "Annual Meeting"). |
prnewswire.com |
2025-05-07 16:50:00 |
Czytaj oryginał (ang.) |
| All Three Leading Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend Tejon Ranch Shareholders Vote “FOR” ONLY Tejon's 10 Director Nominees |
TEJON RANCH, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE: TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today announced that Egan-Jones Proxy Services (“Egan-Jones”), has joined Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) in recommending that shareholders vote “FOR” ONLY Tejon's 10 highly-qualified director nominees on the Company's WHITE Proxy Card in connection with its Annual Meeting of Shareholders scheduled for May 13, 2025. Additional information, including details on how to vote, can be found at www.VoteForTejon.com. |
globenewswire.com |
2025-05-05 20:45:00 |
Czytaj oryginał (ang.) |
| Shareholders of Tejon Ranch Co. Urged to Vote for an Accountable Board of Directors |
SADDLE BROOK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Special Opportunities Fund, Inc. (NYSE: SPE) and Bulldog Investors, LLP (together, “Bulldog”), holders of 2.1% of Tejon Ranch Co., urge shareholders of Tejon Ranch Co. (NYSE: TRC) (“Tejon”) to vote to elect Andrew Dakos, Phillip Goldstein, and Aaron Morris as directors. Bulldog strongly believes that electing these nominees to Tejon's ten-person Board of Directors, will result in greater transparency and accountability and a higher stock price. |
globenewswire.com |
2025-05-05 18:08:00 |
Czytaj oryginał (ang.) |
| Both Leading Proxy Advisory Firms – ISS and Glass Lewis – Recommend Shareholders Vote “FOR” ONLY Tejon's 10 Director Nominees |
ISS's and Glass Lewis's Reports Reinforce That Tejon's Existing Directors Are Best Positioned to Protect Shareholder Value |
globenewswire.com |
2025-05-05 13:15:00 |
Czytaj oryginał (ang.) |
| Leading Proxy Advisory Firm ISS Recommends Shareholders Vote “FOR” ONLY Tejon's 10 Director Nominees |
TEJON RANCH, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE: TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today announced that Institutional Shareholder Services (ISS) has recommended that shareholders vote “FOR” ONLY Tejon's 10 highly-qualified director nominees on the Company's WHITE Proxy Card in connection with its Annual Meeting of Shareholders scheduled for May 13, 2025. |
globenewswire.com |
2025-05-02 22:00:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Emphasizes Commitment to Execution, Oversight and Transparency |
Bulldog's Apparent Lack of Understanding of Tejon's Business Risks Significant Value Destruction at Tejon Urges Shareholders to Vote “FOR” ALL of Tejon Ranch's 10 Highly Qualified Director Nominees on the WHITE Proxy Card TEJON RANCH, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today announced that it has mailed a letter to shareholders in connection with its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) to be held on May 13, 2025. |
globenewswire.com |
2025-05-01 13:15:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. to Participate in Oppenheimer's 20th Annual Industrial Growth Conference |
TEJON RANCH, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today announced that it will participate at Oppenheimer's 20th Annual Growth Conference (virtual format) on Tuesday, May 6, 2025. |
globenewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Harvey Capital Urges Tejon Ranch Co. Shareholders to Vote with Bulldog Investors, Citing Decades of Stagnant Share Price |
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Harvey Capital, a holder of 5,531 shares of Tejon Ranch Co., has issued a letter to shareholders of Tejon Ranch Co. (NYSE: TRC), strongly urging them to vote FOR the nominees proposed by Bulldog Investors at the upcoming Annual Meeting on May 13, 2025. The letter asserts that the current board of directors has been ineffective at delivering a meaningful increase in share price for several decades, underscoring the need for a change in leadership and strategic direction. |
globenewswire.com |
2025-04-30 15:54:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Files Investor Presentation Highlighting Strategy for Significant Long-Term Value Creation |
Tejon's Board Continues to Take Decisive Strategic Steps to Drive the Company's Growth at Tejon Ranch Commerce Center and is Uniquely Positioned to Advance the Value of its Master-Planned Communities |
globenewswire.com |
2025-04-22 13:15:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Successfully Executing Proven Value-Creation Strategy For Our Shareholders |
Urges Shareholders to Vote “FOR” ONLY Tejon's Highly Qualified Director Nominees on the Company's WHITE Proxy Card TODAY |
globenewswire.com |
2025-04-19 01:15:00 |
Czytaj oryginał (ang.) |
| TRC Amends Its Tender Offer for Ingersoll Rand Inc. |
TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- TRC Capital Investment Corporation (TRC) announced today that based on current market conditions, TRC has amended the terms of its tender offer for up to 1,500,000 common shares of Ingersoll Rand Inc. (the Company) and has decreased the offer price payable to US$65.25 per share from US$77.50 per share. |
globenewswire.com |
2025-04-09 13:00:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Reiterates Commitment to Shareholder Value Creation and Highlights Successful Execution of Long-Term Operating Strategy |
Files Definitive Proxy Materials and Mails Letter to Shareholders Urges Shareholders to Vote “FOR” Only Tejon's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY TEJON RANCH, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today filed definitive proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) to be held on May 13, 2025. |
globenewswire.com |
2025-04-03 20:15:00 |
Czytaj oryginał (ang.) |
| Ingersoll Rand Recommends Rejection of TRC Capital's “Mini-Tender” Offer |
DAVIDSON, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Ingersoll Rand Inc. (NYSE: IR), a global provider of mission-critical flow creation and life sciences and industrial solutions, today announced that it received notice of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (TRC Capital) to purchase up to 1,500,00 shares of Ingersoll Rand's common stock at $77.50 per share. The offer price is approximately 4.27% below the closing price of the company's common stock on The New York Stock Exchange on March 21, 2025 ($80.96), the last trading day before the date of the offer. The offer price is also approximately 2.43% below the closing price of Ingersoll Rand's common stock on March 28, 2025 ($79.43), the business day prior to this release. |
globenewswire.com |
2025-03-31 11:15:00 |
Czytaj oryginał (ang.) |
| Monster Beverage Corporation Recommends Stockholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation |
CORONA, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) today announced that it has received notice that TRC Capital Investment Corporation (“TRC”) commenced an unsolicited “mini-tender” offer to purchase up to 2,000,000 shares of the Company's common stock, which represents approximately 0.2% of the Company's outstanding common stock, at a price of $52.95 per share in cash. TRC's offer price of $52.95 is approximately 5.1% less than the closing price of $55.77 of the Company's common stock on March 10, 2025, the last trading day before the date of the offer. |
globenewswire.com |
2025-03-14 16:00:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Announces Fourth Quarter and Year-Ended December 31, 2024 Financial Results |
TEJON RANCH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE:TRC), ("Tejon" or the "Company"), a diversified real estate development and agribusiness company, today announced financial results for the fourth quarter and year-ended December 31, 2024. |
globenewswire.com |
2025-03-06 11:15:00 |
Czytaj oryginał (ang.) |
| TRC Announces Termination of the Tender Offer for Canadian Natural Resources Limited |
TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TRC Capital Investment Corporation (“TRC”) announced today that it has terminated its previously announced cash tender offer to purchase up to 2,500,000 common shares (the “Shares”) of Canadian Natural Resources Limited. All Shares that have been validly tendered (and not validly withdrawn) will be returned promptly to the respective holders thereof without any action required on the part of the holders. No consideration will be paid in the Tender Offer for any tendered Shares. |
globenewswire.com |
2025-02-26 19:00:00 |
Czytaj oryginał (ang.) |
| Lamb Weston Responds to TRC Capital's “Mini-Tender” Offer |
EAGLE, Idaho--(BUSINESS WIRE)--Lamb Weston Holdings, Inc. (NYSE: LW) announced today that it has received notice of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (TRC) dated February 11, 2025, to purchase up to 2,000,000 shares of Lamb Weston's common stock at a price of $55.95 per share in cash. TRC's offer price of $55.95 per share is approximately 4.34% lower than the $58.49 closing share price of Lamb Weston's common stock on February 10, 2025, the business day pr. |
businesswire.com |
2025-02-13 18:30:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Company Announces Appointment of New President & CEO |
TEJON RANCH, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Today, the Board of Directors for the Tejon Ranch Company (NYSE: TRC) announced the unanimous selection of Matthew (Matt) Walker as the company's next President and CEO. |
globenewswire.com |
2025-02-11 11:15:00 |
Czytaj oryginał (ang.) |
| Canadian Natural Resources Limited Cautions Investors Regarding TRC Capital's Below Market "Mini-Tender" Offer |
Calgary, Alberta--(Newsfile Corp. - January 22, 2025) - Canadian Natural Resources Limited (TSX: CNQ) (NYSE: CNQ) ("Canadian Natural" or the "Company") has received notice of an unsolicited "mini-tender" offer made by TRC Capital Investment Corporation ("TRC Capital") to purchase up to 2,500,000 Canadian Natural common shares, or approximately 0.12% of Canadian Natural's outstanding shares, at a price of C$43.25 per share. The offering price represents a discount of 4.44% to the closing price of Canadian Natural's shares on the Toronto Stock Exchange (the "TSX") on January 14, 2025, the last trading day before the mini-tender offer was commenced, and a 4.71% discount to the closing price of the Canadian Natural shares on the TSX on January 22, 2025. |
newsfilecorp.com |
2025-01-22 20:13:00 |
Czytaj oryginał (ang.) |
| Merck Recommends Rejection of TRC Capital's “Mini-Tender” Offer |
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Recommends Rejection of TRC Capital's “Mini-Tender” Offer. |
businesswire.com |
2024-11-22 18:17:00 |
Czytaj oryginał (ang.) |
| Land Rich, Profit Poor: Unpacking Tejon Ranch's Ambitions |
Tejon Ranch Co. is a high-risk stock with inconsistent financials, a sky-high P/E ratio, and ongoing legal issues, making it a 'Sell.' Despite a recent performance boost, Tejon Ranch's revenue has been declining, and large real estate projects are stalled due to environmental lawsuits. The company is heavily investing in real estate projects, but these are not yet profitable, leading to increased debt and operational losses. |
seekingalpha.com |
2024-11-07 14:16:41 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Announces Third Quarter 2024 Financial Results |
TEJON RANCH, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the three and nine-months ended September 30, 2024. |
globenewswire.com |
2024-11-07 11:15:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Announces Addition of Four Board Members |
TEJON RANCH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (TRC: NYSE) is pleased to announce the election of four seasoned professionals to its Board of Directors – Denise Gammon, Kenneth Yee, Jeff McCall and Eric Speron. |
globenewswire.com |
2024-11-05 15:57:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Company and Dedeaux Properties Announce Joint Venture to Develop Industrial Warehouse at the Tejon Ranch Commerce Center |
TEJON RANCH, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Company (NYSE: TRC) announced today that it has signed a joint venture agreement with Dedeaux Properties to develop and lease an approximately 510,500-square-foot, state-of-the-art industrial warehouse at the Tejon Ranch Commerce Center (TRCC). Located at the intersection of Interstate 5 and Highway 99, TRCC is a mixed-use master planned community that operates as an important logistics hub serving all of California and the western United States, driving economic growth for Kern County. |
globenewswire.com |
2024-10-10 22:42:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Names New Senior Vice President- Corporate Communications and Public Affairs |
TEJON RANCH, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE: TRC) announced today that Nicholas (Nick) T. |
globenewswire.com |
2024-09-24 20:15:00 |
Czytaj oryginał (ang.) |
| Magna Recommends Rejection of "Mini-Tender" Offer |
AURORA, Ontario, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today reported that it has received notice of an unsolicited mini-tender offer made by TRC Capital Investment Corporation (“TRC Capital”) to purchase up to 2,000,000 Magna Common Shares, or less than 1% of Magna's outstanding Common Shares, at a price of CDN $57.90 per share. Magna cautions shareholders that the mini-tender offer has been made at a price below recent market prices, representing a discount of 4.49% to the closing price of Magna's Common Shares on the Toronto Stock Exchange (“TSX”) on July 29, 2024, the last trading day before the mini-tender offer commenced. Although the offering price represents a premium of 7.58% to yesterday's closing price of Magna Common Shares on the TSX of CDN $53.82, the offer is highly conditional. TRC Capital's offer states that it may withdraw its offer if, among other things, the market price of Magna Common Shares falls below CDN $57.58, for reference, the closing price on the TSX for Magna Common Shares on August 8, 2024, was CDN $53.82, which is already below this threshold; additionally, TRC Capital's offer is not fully funded and is conditioned upon receipt of necessary financing on terms it deems reasonable in its sole discretion. |
globenewswire.com |
2024-08-09 10:00:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Announces Second Quarter 2024 Financial Results |
TEJON RANCH, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the three and six-months ended June 30, 2024. |
globenewswire.com |
2024-08-06 13:15:00 |
Czytaj oryginał (ang.) |
| Hydro One Limited recommends shareholders reject TRC Capital's below-market "mini tender" offer for common shares |
TORONTO , July 22, 2024 /PRNewswire/ - Hydro One Limited (TSX: H) ("Hydro One") has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC Capital") to purchase up to 2,500,000 common shares of Hydro One ("common shares"), or approximately 0.42% of the outstanding common shares of Hydro One as at July 19, 2024, at a below-market price of CAD$38.10 per share in cash. Hydro One does not endorse TRC Capital's unsolicited offer, is not affiliated or associated with TRC Capital or its offer and recommends that shareholders do not tender their common shares to the offer. |
prnewswire.com |
2024-07-22 21:01:00 |
Czytaj oryginał (ang.) |
| TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients |
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy |
globenewswire.com |
2024-06-11 12:00:00 |
Czytaj oryginał (ang.) |
| Solventum Cautions Investors Regarding TRC Capital's "Mini-Tender Offer" |
ST. PAUL, Minn., June 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) has been notified that TRC Capital Investment Corporation ("TRC") made an unsolicited "mini-tender offer" to purchase up to 2,000,000 shares of the company's common stock at $59.15 per share and decreased the offer price on June 6, 2024, to $55.00 per share. |
prnewswire.com |
2024-06-07 10:55:00 |
Czytaj oryginał (ang.) |
| TRC Amends Its Tender Offer for Solventum Corporation |
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- TRC Capital Investment Corporation (TRC) announced today that based on current market conditions, TRC has amended the terms of its tender offer for up to 2,000,000 common shares of Solventum Corporation (the Company) and has decreased the offer price payable to US$55.00 per share from US$59.15 per share. |
globenewswire.com |
2024-06-06 13:00:00 |
Czytaj oryginał (ang.) |
| GLENBROOK CAPITAL MANAGEMENT RELEASES OPEN LETTER TO TEJON RANCH BOARD CALLING FOR TRANSPARENCY |
Urges Company to Conduct Periodic Investor Calls and Adopt Investor Outreach Program Believes Transparency and Engagement Will Help Unlock Tejon's Value PALO ALTO, Calif. , May 23, 2024 /PRNewswire/ -- Glenbrook Capital Management ("Glenbrook" or "we"), a long-time shareholder of Tejon Ranch Co. (NYSE:TRC) ("Tejon"), today issued the following open letter to the Chairman of the Nominating and Corporate Governance Committee of Tejon's Board of Directors May 23, 2024 Tejon Ranch Co.P.O. |
prnewswire.com |
2024-05-23 20:28:00 |
Czytaj oryginał (ang.) |
| Amalgamated Bank Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) |
Amalgamated Bank boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,119 shares of the biopharmaceutical company’s stock after purchasing an additional 57 shares during the period. Amalgamated Bank’s holdings in Madrigal Pharmaceuticals were worth $490,000 as of its most recent SEC filing. A number of other institutional investors have also recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Madrigal Pharmaceuticals by 21.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 367 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in Madrigal Pharmaceuticals by 53.2% in the third quarter. Glenmede Trust Co. NA now owns 1,567 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 544 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new position in Madrigal Pharmaceuticals in the third quarter valued at about $314,000. Charles Schwab Investment Management Inc. grew its position in shares of Madrigal Pharmaceuticals by 11.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 109,501 shares of the biopharmaceutical company’s stock valued at $15,992,000 after acquiring an additional 11,083 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Madrigal Pharmaceuticals by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,573,338 shares of the biopharmaceutical company’s stock worth $229,770,000 after purchasing an additional 107,816 shares during the last quarter. Institutional investors own 98.50% of the company’s stock. Madrigal Pharmaceuticals Stock Performance NASDAQ MDGL opened at $220.06 on Monday. The company’s 50 day simple moving average is $234.43 and its two-hundred day simple moving average is $221.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.39 and a quick ratio of 9.39. Madrigal Pharmaceuticals, Inc. has a 1 year low of $119.76 and a 1 year high of $302.68. The stock has a market capitalization of $4.69 billion, a PE ratio of -9.53 and a beta of -0.33. Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($7.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.06) by ($1.32). During the same period in the prior year, the firm posted ($4.23) earnings per share. Analysts predict that Madrigal Pharmaceuticals, Inc. will post -27.62 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Several equities analysts have weighed in on the company. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a report on Friday, April 12th. B. Riley cut their price target on Madrigal Pharmaceuticals from $270.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. TD Cowen boosted their price objective on Madrigal Pharmaceuticals from $349.00 to $390.00 and gave the company an “outperform” rating in a research note on Friday, March 15th. UBS Group increased their target price on shares of Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $336.00 target price on shares of Madrigal Pharmaceuticals in a research note on Thursday, March 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $345.09. Read Our Latest Report on Madrigal Pharmaceuticals Insider Buying and Selling at Madrigal Pharmaceuticals In related news, Director Richard S. Levy sold 11,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $257.48, for a total value of $2,832,280.00. Following the transaction, the director now directly owns 10,298 shares in the company, valued at $2,651,529.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CMO Rebecca Taub sold 2,676 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, April 8th. The shares were sold at an average price of $245.99, for a total transaction of $658,269.24. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares of the company’s stock, valued at approximately $112,909,164.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard S. Levy sold 11,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $257.48, for a total transaction of $2,832,280.00. Following the completion of the transaction, the director now owns 10,298 shares of the company’s stock, valued at $2,651,529.04. The disclosure for this sale can be found here. Insiders have sold a total of 168,985 shares of company stock valued at $36,149,878 in the last 90 days. Corporate insiders own 23.92% of the company’s stock. Madrigal Pharmaceuticals Company Profile (Free Report) Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. |
https://www.defenseworld.net |
2024-05-20 09:00:51 |
Czytaj oryginał (ang.) |
| Swiss National Bank Sells 9,000 Shares of Envestnet, Inc. (NYSE:ENV) |
Swiss National Bank lessened its holdings in shares of Envestnet, Inc. (NYSE:ENV – Free Report) by 10.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 80,700 shares of the business services provider’s stock after selling 9,000 shares during the quarter. Swiss National Bank owned about 0.15% of Envestnet worth $3,996,000 at the end of the most recent quarter. Other large investors also recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in Envestnet during the 3rd quarter valued at approximately $45,000. PNC Financial Services Group Inc. increased its holdings in Envestnet by 19.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,930 shares of the business services provider’s stock valued at $217,000 after acquiring an additional 802 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Envestnet by 75.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,788 shares of the business services provider’s stock worth $299,000 after purchasing an additional 2,915 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Envestnet during the 3rd quarter valued at about $420,000. Finally, Truist Financial Corp purchased a new position in shares of Envestnet during the fourth quarter valued at about $433,000. Insider Buying and Selling at Envestnet In other news, insider Matthew Majoros sold 700 shares of the stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $56.92, for a total transaction of $39,844.00. Following the transaction, the insider now directly owns 15,212 shares in the company, valued at $865,867.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Lauren Taylor Wolfe acquired 1,670 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were bought at an average price of $52.99 per share, with a total value of $88,493.30. Following the completion of the transaction, the director now directly owns 4,188,871 shares in the company, valued at $221,968,274.29. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Matthew Majoros sold 700 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $56.92, for a total transaction of $39,844.00. Following the sale, the insider now directly owns 15,212 shares of the company’s stock, valued at $865,867.04. The disclosure for this sale can be found here. Insiders own 8.90% of the company’s stock. Envestnet Price Performance ENV opened at $67.81 on Monday. The business has a fifty day moving average of $60.10 and a 200 day moving average of $51.46. The stock has a market cap of $3.74 billion, a P/E ratio of -19.05 and a beta of 1.26. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 1.47. Envestnet, Inc. has a 52-week low of $33.12 and a 52-week high of $68.83. Envestnet (NYSE:ENV – Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The business services provider reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.10. The company had revenue of $317.63 million during the quarter, compared to analyst estimates of $312.24 million. Envestnet had a negative net margin of 15.33% and a positive return on equity of 14.75%. As a group, sell-side analysts anticipate that Envestnet, Inc. will post 1.78 EPS for the current year. Wall Street Analyst Weigh In ENV has been the subject of a number of research reports. Jefferies Financial Group raised Envestnet from an “underperform” rating to a “hold” rating and increased their price target for the company from $47.00 to $59.00 in a research note on Wednesday, May 8th. DA Davidson lifted their price objective on shares of Envestnet from $62.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. JPMorgan Chase & Co. upped their target price on shares of Envestnet from $44.00 to $45.00 and gave the company a “neutral” rating in a research report on Friday, February 23rd. Raymond James lifted their price target on Envestnet from $52.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 2nd. Finally, Royal Bank of Canada boosted their target price on Envestnet from $56.00 to $64.00 and gave the company a “sector perform” rating in a research report on Wednesday, May 8th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $64.14. Check Out Our Latest Analysis on Envestnet Envestnet Company Profile (Free Report) Envestnet, Inc, through its subsidiaries, provides wealth management software and services in the United States and internationally. It operates through two segments: Envestnet Wealth Solutions and Envestnet Data & Analytics. The Envestnet Wealth Solutions segment offers Envestnet | Enterprise, an end-to-end open architecture wealth management platform, as well as offers data aggregation and reporting, data analytics, and digital advice capabilities; Envestnet | Wealth Analytics that transforms data into actionable intelligence; Envestnet | Tamarac which provides trading, rebalancing, portfolio accounting, performance reporting, and client relationship management software; and Envestnet | MoneyGuide that provides goals-based financial planning solutions to the financial services industry. |
https://www.defenseworld.net |
2024-05-20 08:42:49 |
Czytaj oryginał (ang.) |
| Research Analysts Offer Predictions for Dianthus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:DNTH) |
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – HC Wainwright issued their Q2 2024 EPS estimates for Dianthus Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.28) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.16) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q3 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.65) EPS, Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($3.82) EPS, FY2027 earnings at ($4.30) EPS and FY2028 earnings at ($3.26) EPS. Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.40. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.73 million. Several other equities research analysts also recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating and a $44.00 price objective for the company. Jefferies Financial Group lifted their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Raymond James lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. Finally, Wedbush boosted their target price on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $42.83. Get Our Latest Report on Dianthus Therapeutics Dianthus Therapeutics Trading Down 2.4 % NASDAQ DNTH opened at $25.63 on Monday. The firm’s fifty day simple moving average is $25.63 and its two-hundred day simple moving average is $18.97. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77. The firm has a market capitalization of $752.21 million, a P/E ratio of -4.40 and a beta of 1.77. Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new position in Dianthus Therapeutics in the fourth quarter valued at $25,000. Citigroup Inc. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $53,000. Hussman Strategic Advisors Inc. purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth about $630,000. Acadian Asset Management LLC purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $303,000. Finally, Laurion Capital Management LP purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $497,000. Hedge funds and other institutional investors own 47.53% of the company’s stock. Dianthus Therapeutics Company Profile (Get Free Report) Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. See Also Five stocks we like better than Dianthus Therapeutics Retail Stocks Investing, Explained MarketBeat Week in Review – 5/13 – 5/17 Why Invest in Biotech Stocks Take-Two Interactive Software Offers 2nd Chance for Investors 3 Grocery Stocks That Can Help Take a Bite Out of Inflation Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 05:38:50 |
Czytaj oryginał (ang.) |
| Q2 2024 Earnings Forecast for Despegar.com, Corp. Issued By B. Riley (NYSE:DESP) |
Despegar.com, Corp. (NYSE:DESP – Free Report) – Equities researchers at B. Riley reduced their Q2 2024 earnings per share estimates for shares of Despegar.com in a note issued to investors on Friday, May 17th. B. Riley analyst N. Khan now expects that the company will post earnings of $0.14 per share for the quarter, down from their previous forecast of $0.15. B. Riley has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Despegar.com’s current full-year earnings is $0.76 per share. B. Riley also issued estimates for Despegar.com’s Q3 2024 earnings at $0.20 EPS, Q4 2024 earnings at $0.43 EPS, FY2024 earnings at $0.96 EPS and FY2025 earnings at $1.49 EPS. A number of other brokerages have also recently commented on DESP. Cantor Fitzgerald lifted their price target on Despegar.com from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday. Citigroup reaffirmed a “neutral” rating and set a $14.50 price target (up previously from $11.50) on shares of Despegar.com in a research report on Monday, April 29th. Check Out Our Latest Report on DESP Despegar.com Stock Up 19.1 % Shares of DESP opened at $14.94 on Monday. The stock has a 50-day moving average of $12.00 and a two-hundred day moving average of $9.86. Despegar.com has a one year low of $5.55 and a one year high of $15.54. Hedge Funds Weigh In On Despegar.com Institutional investors and hedge funds have recently modified their holdings of the stock. Activest Wealth Management acquired a new position in shares of Despegar.com in the 1st quarter valued at about $39,000. Tucker Asset Management LLC acquired a new position in Despegar.com in the 4th quarter worth about $40,000. Tower Research Capital LLC TRC raised its holdings in Despegar.com by 83.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,617 shares of the company’s stock worth $44,000 after purchasing an additional 2,104 shares during the period. Quantbot Technologies LP acquired a new position in Despegar.com in the 3rd quarter worth about $74,000. Finally, Counterpoint Mutual Funds LLC acquired a new position in Despegar.com in the 4th quarter worth about $99,000. Institutional investors and hedge funds own 67.93% of the company’s stock. About Despegar.com (Get Free Report) Despegar.com, Corp., an online travel company, provides a range of travel and travel-related products to leisure and corporate travelers through its websites and mobile applications in Latin America and the United States. The company operates in two segments, Travel Business and Financial Services Business. |
https://www.defenseworld.net |
2024-05-20 05:38:43 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Announces First Quarter 2024 Financial Results |
TEJON RANCH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the three-months ended March 31, 2024. |
globenewswire.com |
2024-05-07 13:15:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch President and CEO Announces Retirement Date |
TEJON RANCH, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (TRC-NYSE). Today, Mr. Gregory Bielli, President, and Chief Executive Officer (CEO) of Tejon Ranch Co., announced his intent to retire on December 31, 2024. Mr. Bielli has been President and CEO of Tejon Ranch Co. for over 10 years, since 2013. Mr. Bielli joined the company to create an integrated real estate company that now includes planning, entitlements, construction, sales and leasing of all classes of real estate assets and growing its non-real estate platform. Mr. Bielli has successfully accomplished these goals for the company during his tenure. |
globenewswire.com |
2024-03-20 18:15:00 |
Czytaj oryginał (ang.) |
| Tejon Ranch Co. Announces Fourth Quarter and Year-Ended December 31, 2023 Financial Results |
TEJON RANCH, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the fourth quarter and year-ended December 31, 2023. |
globenewswire.com |
2024-03-06 11:15:00 |
Czytaj oryginał (ang.) |